Salarius Pharmaceuticals Inc (SLRX)

Jan 07, 2026

Salarius Pharmaceuticals changes name to Decoy Therapeutics - MarketScreener

Jan 07, 2026

Jan 07, 2026

Salarius Pharmaceuticals to rebrand as Decoy Therapeutics, change ticker By Investing.com - Investing.com Australia

Jan 07, 2026

Jan 07, 2026

Salarius Pharmaceuticals stock soars on name change to Decoy Therapeutics By Investing.com - Investing.com Australia

Jan 07, 2026

Jan 07, 2026

Salarius Pharmaceuticals stock soars on name change to Decoy Therapeutics - Investing.com

Jan 07, 2026

Jan 07, 2026

Salarius Pharmaceuticals, Inc. Announces Rebranding to Decoy Therapeutics Inc. with Nasdaq Trading Under DCOY Starting January 8, 2026 - Quiver Quantitative

Jan 07, 2026

Jan 07, 2026

Biotech rebrands as Decoy Therapeutics to pursue next-gen antivirals - Stock Titan

Jan 07, 2026

Jan 07, 2026

Salarius Pharmaceuticals appeals Nasdaq delisting after bid deficiency - MSN

Jan 07, 2026

Jan 06, 2026

Salarius Pharmaceuticals shareholders re-elect directors and approve proposals at annual meeting - Investing.com Nigeria

Jan 06, 2026

Jan 04, 2026

Salarius Pharmaceuticals and Decoy Therapeutics announce merger - MSN

Jan 04, 2026

Jan 03, 2026

Salarius Pharmaceuticals (NASDAQ:SLRX) Downgraded by Wall Street Zen to Sell - Defense World

Jan 03, 2026

Jan 02, 2026

Salarius Pharmaceuticals Inc. (SLRX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade

Jan 02, 2026

Jan 02, 2026

Salarius Shareholders Back Directors, Executive Pay and Auditor - TipRanks

Jan 02, 2026

Jan 02, 2026

Salarius Pharmaceuticals Appeals Nasdaq Delisting After Bid Deficiency - TipRanks

Jan 02, 2026

Jan 02, 2026

Salarius Pharmaceuticals faces potential Nasdaq delisting after bid price rule breach By Investing.com - Investing.com South Africa

Jan 02, 2026

Jan 02, 2026

Salarius Pharmaceuticals shareholders re-elect directors and approve proposals at annual meeting By Investing.com - Investing.com South Africa

Jan 02, 2026

Jan 02, 2026

Hanish, director at Salarius, sells shares worth $17 By Investing.com - Investing.com Nigeria

Jan 02, 2026

Jan 02, 2026

Hanish, director at Salarius, sells shares worth $17 - Investing.com

Jan 02, 2026

Jan 02, 2026

Salarius Pharmaceuticals faces potential Nasdaq delisting after bid price rule breach - Investing.com

Jan 02, 2026

Jan 02, 2026

Salarius Pharmaceuticals (NASDAQ: SLRX) appeals Nasdaq delisting over $1.00 bid rule - Stock Titan

Jan 02, 2026

Dec 31, 2025

Salarius shareholders back directors, executive pay and auditor - MSN

Dec 31, 2025

Dec 24, 2025

Salarius announces planned corporate name change to Decoy Therapeutics - MSN

Dec 24, 2025

Dec 20, 2025

Salarius Pharmaceuticals stock tumbles after announcing $7 million discounted public offering - MSN

Dec 20, 2025

Dec 20, 2025

Can Salarius Pharmaceuticals Inc. stock hit analyst price targets2025 Valuation Update & Fast Moving Market Watchlists - Улправда

Dec 20, 2025

Dec 20, 2025

Wall Street Recap: Can Salarius Pharmaceuticals Inc. (FP10) stock hit consensus price targetsWeekly Market Report & Fast Entry Momentum Alerts - Улправда

Dec 20, 2025

Dec 20, 2025

Salarius Pharmaceuticals Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting - The Manila Times

Dec 20, 2025

Dec 19, 2025

Salarius Pharmaceuticals adjourns annual meeting over quorum shortfall - MSN

Dec 19, 2025

Dec 19, 2025

Investment Review: Will Salarius Pharmaceuticals Inc. stock benefit from infrastructure spendingWeekly Trading Summary & Fast Moving Stock Watchlists - Улправда

Dec 19, 2025

Dec 19, 2025

Salarius Pharmaceuticals Adjourns Annual Meeting Over Quorum Shortfall - TipRanks

Dec 19, 2025

Dec 19, 2025

Salarius Pharmaceuticals adjourns annual meeting due to low turnout By Investing.com - Investing.com Nigeria

Dec 19, 2025

Dec 19, 2025

Can Salarius Pharmaceuticals Inc. (FP10) stock hit consensus price targets2025 EndofYear Setup & Expert Verified Stock Movement Alerts - Улправда

Dec 19, 2025

Dec 19, 2025

Salarius Pharmaceuticals adjourns annual meeting due to low turnout - Investing.com

Dec 19, 2025

Dec 19, 2025

Is Salarius Pharmaceuticals Inc. stock gaining market share2025 Retail Activity & Stock Portfolio Risk Management - DonanımHaber

Dec 19, 2025

Dec 19, 2025

What dividend safety rating applies to Salarius Pharmaceuticals Inc. (FP10) stockPortfolio Return Report & Fast Gain Stock Tips - DonanımHaber

Dec 19, 2025

Dec 19, 2025

Is Salarius Pharmaceuticals Inc. stock affected by interest rate hikesWeekly Market Summary & Detailed Earnings Play Alerts - Улправда

Dec 19, 2025

Dec 19, 2025

What makes Salarius Pharmaceuticals Inc. stock attractive to growth fundsSwing Trade & Real-Time Stock Entry Alerts - DonanımHaber

Dec 19, 2025

Dec 18, 2025

Barbara Louise Hibner Net Worth (2025) - GuruFocus

Dec 18, 2025

Dec 18, 2025

Salarius to change name to Decoy Therapeutics, adopt DCOY ticker By Investing.com - Investing.com Nigeria

Dec 18, 2025

Dec 18, 2025

Salarius Pharmaceuticals to Change Name to Decoy Therapeutics - marketscreener.com

Dec 18, 2025

Dec 18, 2025

Salarius Pharmaceuticals (SLRX) to Rebrand as Decoy Therapeutics - GuruFocus

Dec 18, 2025

Dec 18, 2025

SLRX Insider Trading - Quiver Quantitative

Dec 18, 2025

Dec 18, 2025

Salarius to change name to Decoy Therapeutics, adopt DCOY ticker - Investing.com

Dec 18, 2025

Dec 18, 2025

Salarius Pharmaceuticals announces name and ticker change to Decoy Therapeutics - marketscreener.com

Dec 18, 2025

Dec 18, 2025

Salarius Pharmaceuticals, Inc. Transforms into Decoy Therapeutics, Inc. with NASDAQ Ticker Change to DCOY Effective January 2026 - Quiver Quantitative

Dec 18, 2025

Dec 18, 2025

Decoy Therapeutics pivots to next-gen antivirals for multi-virus threats - Stock Titan

Dec 18, 2025

Dec 17, 2025

NanOlogy names David Arthur as CEO - Fort Worth Report

Dec 17, 2025

Dec 15, 2025

Salarius Pharmaceuticals Earnings Notes - Trefis

Dec 15, 2025